Showing 2641-2650 of 6036 results for "".
- Johnson & Johnson Vision to Present and Support 43 Company-Sponsored and Investigator-Led Studies at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-and-support-43-company-sponsored-and-investigator-led-studies-at-ascrs/2481593/Johnson & Johnson Vision will present and support 43 company-sponsored and investigator-led studies evaluating innovation, outcomes and satisfaction rates across its surgical portfolio at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, May 5-8
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic Systemhttps://modernod.com/news/bausch-lomb-announces-us-launch-of-stablevisc-cohesive-ophthalmic-viscosurgical-device-and-totalvisc-viscoelastic-system/2481555/Bausch + Lomb announced the US launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc Viscoelastic System. StableVis
- Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through Recycling Programshttps://modernod.com/news/bausch-lomb-reports-more-than-65-million-units-of-contact-lens-eye-care-and-lens-care-materials-recycled-through-one-by-one-and-biotrue-eye-care-recycling-programs/2481540/Bausch + Lomb announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.
- CORE Demonstrates Advanced 3D Printing for Ocular Research at ARVO 2023https://modernod.com/news/core-demonstrates-advanced-3d-printing-for-ocular-research-at-arvo-2023/2481539/Scientists from the Centre for Ocular Research & Education (CORE) plan to unveil multiple advancements in 3D printing during the ARVO 2023 Annual Meeting in New Orleans. These innovations may widespread applications, with the potential to accelerate dev
- Nova Eye Medical Announces US Market Clearance of the iTrack Advance Canaloplasty Devicehttps://modernod.com/news/nova-eye-medical-announces-us-market-clearance-of-the-itrack-advance-canaloplasty-device/2481530/Nova Eye Medical announced that it has been granted FDA 510(k) clearance for its new canaloplasty device, iTrack Advance. The iTrack Advance has been cleared for microcatheterization and viscodilation to reduce IOP in adult patients with prim